Longeveron (LGVN) Profit After Tax (2020 - 2026)
Longeveron's (LGVN) quarterly Profit After Tax came in at -$4.7 million in Q1 2026, up 5.49% year-on-year from -$4.5 million in Q1 2025, and up 12.36% quarter-over-quarter from -$5.4 million in Q4 2025.
Longeveron (LGVN) Profit After Tax (2020 - 2026) Analysis & Trends
Longeveron's Profit After Tax history runs 7 years deep, the most recent figure standing at -$4.7 million for Q1 2026.
- On a quarterly basis, Profit After Tax rose 5.49% year-over-year to -$4.7 million in Q1 2026; TTM through Mar 2026 was -$22.4 million, a 32.35% decrease from a year earlier, with the FY2025 full-year figure at -$22.7 million, down 42.14% from the prior year.
- Profit After Tax improved to -$4.7 million in Q1 2026 per LGVN's latest filing, from -$5.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$3.4 million in Q2 2024 and bottomed at -$7.2 million in Q3 2025.
- The 5-year median for Profit After Tax is -$5.0 million (2025), against an average of -$4.9 million.
- Across the five-year window, Profit After Tax surged 39.4% in 2024 and tumbled 63.41% in 2025, its largest moves.
- Year by year, Profit After Tax stood at -$4.5 million in 2022, then sank by 35.25% to -$6.0 million in 2023, then soared by 32.43% to -$4.1 million in 2024, then slumped by 32.68% to -$5.4 million in 2025, then increased by 12.36% to -$4.7 million in 2026.
- Per Business Quant, the three latest LGVN Profit After Tax figures stand at -$4.7 million (Q1 2026), -$5.4 million (Q4 2025), and -$7.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Longeveron | 15.36 Bn | 15.34 Bn | 264,000.00 | -4.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.74 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -7.22 Mn |
| Jun 30, 2025 | -5.03 Mn |
| Mar 31, 2025 | -5.01 Mn |
| Dec 31, 2024 | -4.07 Mn |
| Sep 30, 2024 | -4.42 Mn |
| Jun 30, 2024 | -3.41 Mn |
| Mar 31, 2024 | -4.10 Mn |
| Dec 31, 2023 | -6.03 Mn |
| Sep 30, 2023 | -5.11 Mn |
| Jun 30, 2023 | -5.63 Mn |
| Mar 31, 2023 | -4.60 Mn |
| Dec 31, 2022 | -4.46 Mn |
| Sep 30, 2022 | -5.24 Mn |
| Jun 30, 2022 | -5.62 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | -4.07 Mn |
| Sep 30, 2021 | -4.86 Mn |
| Jun 30, 2021 | -5.01 Mn |